Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.
Greenberg A, Shahriari M, Cameron M, Payette M, Dasilva D, Damiani G, Herman E, Eminger L, Issa N, Rodriguez A, Del Rosso J, Kang Y, Cohen J, Bunick C. Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series. The Journal Of Clinical And Aesthetic Dermatology 2025, 18: 16-19. PMID: 40538523, PMCID: PMC12175839.Peer-Reviewed Original ResearchInvestigator's Global AssessmentAdverse eventsFood and Drug AdministrationAtopic dermatitisInterleukin-4Alternative therapiesSwitching to alternative therapiesSurface area of involvementDiscontinuation of dupilumabDiscontinuation of treatmentT cell populationsChronic inflammatory skin conditionMulti-center case seriesUnited States Food and Drug AdministrationStates Food and Drug AdministrationBody surface areaOptimal clinical outcomesInflammatory skin conditionAD signsTargeting interleukins 4Area of involvementSystemic treatmentT cellsCase seriesClinical outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply